Erratum

Erratum Erratum (1200) Total Article Views Authors: Yeung J, Holinstat M Published Date August 2012 Volume 2012:3 Pages 49 - 50 DOI: http://dx.doi.org/10.2147/JBM.S36176 Received: 20 July 2012 Accepted: Published: 03 August 2012 Yeung J, Holinstat M. Newer agents in antiplatelet therapy: a review. Journal of Blood Medicine. 2012;3:33–42. An error was made on page 37, section GPVI receptor antagonists, in the above paper. The company currently moving Revacept through clinical development is in fact advanceCor GmbH (Martinsried, Germany) and not ABX-CRO/Medifacts GmbH (Goerlitz, Saxony, Germany). Read the original article. Post to: Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter Other articles by Dr Michael Holinstat Newer agents in antiplatelet therapy: a review Readers of this article also read: Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors "Globalized public health.” A transdisciplinary comprehensive framework for analyzing contemporary globalization’s influences on the field of public health The pathophysiology of bronchiectasis Morgellons disease: Analysis of a population with clinically confirmed microscopic subcutaneous fibers of unknown etiology Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine Deep vein thrombosis: a clinical review Phenotype characterization of embryoid body structures generated by a crystal comet effect tail in an intercellular cancer collision scenario Antibiofilm surface functionalization of catheters by magnesium fluoride nanoparticles Insight into 144 patients with ocular vascular events during VEGF antagonist injections